Fluoxetine: Nursing Drug Guide, Serotonin Syndrome & NCLEX Review
Long-acting SSRI for depression, OCD, bulimia, and panic disorder—on shift, the highest-stakes risks are stacking fluoxetine with MAOIs, linezolid, or other serotonergic drugs and missing early serotonin syndrome, plus boxed-warning suicidality monitoring in children, adolescents, and young adults during the first months of therapy and at dose changes.
Fluoxetine carries a boxed warning that antidepressants increase suicidal thoughts and behavior in children, adolescents, and young adults—monitor closely during the first months and at dose changes. Do not use MAOIs intended to treat psychiatric disorders with fluoxetine or within 5 weeks of stopping fluoxetine; allow at least 14 days after stopping an MAOI before starting fluoxetine. Do not start fluoxetine in a patient on linezolid or IV methylene blue. Serotonin syndrome can be life-threatening when fluoxetine is combined with other serotonergic drugs—discontinue fluoxetine and serotonergic agents and initiate supportive treatment immediately if mental status changes, autonomic instability, or neuromuscular hyperactivity occur.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before fluoxetine: perform medication reconciliation for MAOIs, linezolid, tramadol, triptans, lithium, and duplicate SSRIs; confirm at least 14 days since any MAOI and plan a 5-week washout before MAOI starts after fluoxetine stops. Monitor young adults for suicidality and activation symptoms. Hold and escalate immediately for agitation, hyperthermia, clonus, or autonomic instability suggestive of serotonin syndrome.
Most common brand names
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) supplied as oral capsules in 10 mg, 20 mg, and 40 mg strengths. Verify strength and whether the order is for once-daily morning dosing or a titration schedule on every administration pass.
Common U.S. brand examples include Prozac (fluoxetine capsules) and Sarafem (fluoxetine hydrochloride for premenstrual dysphoric disorder). Generic fluoxetine capsules are widely dispensed. Fluoxetine is also a component of fixed-dose combination products with olanzapine (Symbyax) for selected bipolar depression and treatment-resistant depression regimens—those products follow separate combination labeling.
- Capsule strengths: 10 mg, 20 mg, 40 mg per prescribing information
- Look-alike name: Tall-man lettering FLUoxetine appears on some labels to reduce confusion with other psychotropics
- Not interchangeable: Do not substitute combination olanzapine/fluoxetine products for fluoxetine monotherapy without prescriber and pharmacy verification
Why we give it — Indications
Fluoxetine is indicated for acute and maintenance treatment of major depressive disorder (MDD), obsessions and compulsions in obsessive-compulsive disorder (OCD), binge-eating and vomiting behaviors in moderate to severe bulimia nervosa, and acute treatment of panic disorder with or without agoraphobia. Screen for bipolar disorder before starting antidepressant monotherapy—untreated depression in bipolar illness carries suicide risk, but antidepressant monotherapy may precipitate mania in susceptible patients.
| Use | Detail |
|---|---|
| Major depressive disorder (MDD) | Acute and maintenance treatment in adults and defined pediatric age groups per labeling. Full antidepressant effect may be delayed until 4 weeks or longer. |
| Obsessive-compulsive disorder (OCD) | Acute and maintenance treatment. Full therapeutic effect in OCD may be delayed until 5 weeks or longer. |
| Bulimia nervosa | Acute and maintenance treatment of binge-eating and vomiting behaviors in moderate to severe bulimia nervosa at 60 mg/day in trials. |
| Panic disorder | Acute treatment with or without agoraphobia. Typical flexible-dose trial dose was 20 mg/day. |
| Postpartum context | When depression occurs after childbirth, coordinate perinatal mental health pathways; postpartum depression requires suicidality surveillance consistent with the boxed warning. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Although the exact mechanism is unknown, fluoxetine is presumed to work by inhibiting central nervous system neuronal uptake of serotonin. Clinical studies demonstrate blockade of serotonin uptake into human platelets. Fluoxetine is extensively metabolized to the active metabolite norfluoxetine, which also inhibits serotonin reuptake.
Because fluoxetine and norfluoxetine have long elimination half-lives, active drug persists for weeks after the last dose—this underpins the 5-week MAOI washout and delayed attainment of steady state after dose changes. Nurses should not interpret early lack of response as under-dosing without prescriber review, and should treat any new serotonergic drug as a high-risk interaction even days after a missed fluoxetine dose.
Dosing overview
Dosing depends on indication, age, hepatic function, and interacting drugs. Most adult regimens start in the morning. Maximum fluoxetine dose should not exceed 80 mg/day per prescribing information.
Selected pediatric starting doses (labeling)
| Indication | Starting dose | Notes |
|---|---|---|
| MDD (children/adolescents) | 10 or 20 mg/day | After 1 week at 10 mg/day, increase to 20 mg/day; lower-weight children may target 10 mg/day |
| OCD (adolescents/higher-weight children) | 10 mg/day → 20 mg after 2 weeks | Range 20–60 mg/day recommended |
| OCD (lower-weight children) | 10 mg/day | Range 20–30 mg/day recommended; minimal experience above 20 mg in lower-weight children |
On a small screen, swipe or scroll sideways to see the full table.
MAOI switching (critical): At least 14 days between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of fluoxetine. At least 5 weeks after stopping fluoxetine before starting an MAOI intended to treat psychiatric disorders.
Missed dose: Do not double doses. Because of long half-lives, a single missed dose may have limited immediate effect but does not eliminate interaction risk from residual fluoxetine/norfluoxetine—clarify with pharmacy if multiple doses are missed or if serotonergic drugs are newly ordered.
Before you give it — Safety check
Pretreatment checks
- Screen MAR and home list for MAOIs, linezolid, IV methylene blue, other SSRIs/SNRIs, triptans, tramadol, lithium, and St. John’s wort
- Confirm timing since last MAOI or last fluoxetine dose when switching antidepressant classes
- Assess mood, suicidality, sleep, and activation symptoms (anxiety, agitation, insomnia)—especially in patients under 25
- Review seizure history (epilepsy) and drugs that prolong QT (pimozide and thioridazine are contraindicated with fluoxetine)
- Check recent sodium results when available—SSRIs may cause hyponatremia/SIADH; trend sodium if symptoms develop
Contraindications
- MAOIs intended to treat psychiatric disorders with fluoxetine or within 5 weeks of stopping fluoxetine
- Fluoxetine within 14 days of stopping an MAOI intended to treat psychiatric disorders
- Starting fluoxetine in a patient treated with linezolid or IV methylene blue
- Concomitant pimozide or thioridazine (QT prolongation and interaction risk); thioridazine also contraindicated within 5 weeks after fluoxetine discontinuation
- Known hypersensitivity to fluoxetine
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| MAOIs & linezolid | Contraindicated or requires washout—serotonin syndrome, including fatal reactions, reported with MAOI combinations and when switching too early | Hold fluoxetine; verify 5-week washout before MAOI; hold new linezolid orders until prescriber/pharmacy documents a safe plan |
| Tramadol, opioids, triptans, other SSRIs/SNRIs | Increased serotonin syndrome risk, especially at initiation and dose increases | Educate on symptoms; monitor mental status, autonomic signs, and neuromuscular findings; hold and notify same shift if syndrome suspected |
| Sumatriptan and other triptans | Serotonin syndrome risk with serotonergic drugs | Confirm intentional co-therapy; teach patient to report sudden agitation, fever, or rigidity |
| Warfarin, aspirin, NSAIDs | SSRIs may increase bleeding risk; epidemiologic data link SSRI exposure near delivery with increased postpartum hemorrhage risk | Monitor for bruising, GI bleeding, and bleeding after procedures; escalate per anticoagulation protocol |
| Highly protein-bound drugs | Fluoxetine is highly protein bound; interaction with other protein-bound agents not fully evaluated but may be clinically important | Flag new highly bound drugs for pharmacist review when fluoxetine starts or stops |
On a small screen, swipe or scroll sideways to see the full table.
Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. Monitor all patients started on antidepressants for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the first few months and at dose changes. Advise families and caregivers to report behavioral changes immediately.
Administration
Route: Oral capsules (10 mg, 20 mg, 40 mg). May be taken with or without food; food may delay absorption by 1 to 2 hours without clinically significant effect on bioavailability.
- Give morning doses as ordered—activation and insomnia are common early adverse effects
- Swallow capsules whole unless pharmacy approves opening for patients who cannot swallow
- Verify capsule strength before administration—40 mg capsules are a high-strength unit requiring independent double-check when used
- When switching from another antidepressant, confirm washout intervals with pharmacy—do not assume short SSRI half-lives apply to fluoxetine
- Document patient report of adherence; partial adherence still leaves norfluoxetine active for weeks
Fluoxetine elimination half-life is approximately 1 to 3 days after acute administration and 4 to 6 days after chronic administration; norfluoxetine half-life is approximately 4 to 16 days. Active drug persists for weeks after discontinuation—this is why MAOI washout requires 5 weeks, not a few days.
Expected therapeutic response
- Gradual improvement in depressive symptoms over 4 or more weeks for MDD—early weeks may show only partial response
- OCD symptoms may require 5 or more weeks before full therapeutic effect; document functional change, not just patient reassurance
- Reduced panic attack frequency and anticipatory anxiety when used for panic disorder after titration to therapeutic dose
- Decreased binge-eating and purging frequency at 60 mg/day for bulimia nervosa per trial data
- Stable vital signs and mental status without new agitation, mania, or suicidality—therapeutic response must not come at the cost of activation or serotonin toxicity
Red flags — Stop and act
Serotonin syndrome and suicidality are the two escalation pathways nurses must not miss. Discontinue fluoxetine and concomitant serotonergic agents immediately when serotonin syndrome is suspected and initiate supportive treatment per protocol.
- Mental status changes—agitation, hallucinations, delirium, or coma—especially after new tramadol, triptan, or linezolid
- Autonomic instability—tachycardia, labile blood pressure, hyperthermia, diaphoresis
- Neuromuscular hyperactivity—tremor, rigidity, myoclonus, hyperreflexia, incoordination
- Seizures, severe nausea/vomiting/diarrhea cluster with autonomic signs—treat as serotonin syndrome until ruled out
- New or worsening suicidal ideation, self-harm behaviors, or sudden behavioral changes in children, adolescents, or young adults
- Mania/hypomania, racing thoughts, or decreased need for sleep—hold and notify prescriber; may indicate bipolar activation
- Severe rash, angioedema, or systemic allergic signs—stop permanently unless allergy service approves rechallenge
- Symptomatic hyponatremia—headache, confusion, weakness, unsteadiness; severe cases may include seizure or coma
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Nausea, diarrhea, dyspepsia, dry mouth | Common GI effects across MDD, OCD, bulimia, and panic trials | Assess hydration; give with food if tolerated; differentiate from serotonin syndrome GI cluster |
| Insomnia, anxiety, nervousness | Common; insomnia reported in 28% OCD trial vs 22% placebo | Monitor for activation vs improvement; educate on timing of morning dosing; screen for suicidality |
| Somnolence, asthenia, yawning | Common CNS effects | Fall precautions in older adults; assess sedation before ambulation |
| Tremor, sweating, vasodilatation | Common; tremor listed among frequent reactions | Compare to baseline; paired with hyperreflexia and agitation, consider serotonin syndrome |
| Sexual dysfunction | Decreased libido, abnormal ejaculation, impotence reported | Document patient concerns; nonjudgmental teaching; prescriber review if adherence affected |
| Rash | 7% rash/urticaria in U.S. trials; serious cutaneous reactions reported | Stop fluoxetine for systemic or progressive rash; evaluate for DRESS or vasculitis per protocol |
| Bleeding | SSRIs may increase bleeding; concomitant warfarin/NSAIDs add risk | Monitor bruising, hemoglobin drop, melena; perioperative planning with team |
| Hyponatremia/SIADH | Reported with SSRIs; serum sodium below 110 mmol/L reported reversibly | Hold and notify for confusion, headache, falls; repeat sodium and volume status assessment |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Prescribing information does not list a specific reversal agent for fluoxetine overdose. Management is supportive, with activated charcoal considered in patients who present early after ingestion. Co-ingestion with other serotonergic drugs increases serotonin syndrome risk.
Reported overdose findings
- Seizures (may be delayed) and altered mental status including coma
- Cardiovascular toxicity (may be delayed)—QRS and QTc prolongation, wide-complex arrhythmias, torsade de pointes, cardiac arrest; hypertension most common, hypotension possible with co-ingestants
- Serotonin syndrome—especially with multiple pro-serotonergic drugs
Supportive care
- Airway, breathing, circulation; cardiac monitoring for delayed QT and arrhythmias
- Consider gastrointestinal decontamination with activated charcoal when presentation is early
- Treat seizures and hyperthermia per emergency protocol; cooling measures for serotonin syndrome
- Discontinue fluoxetine and other serotonergic agents when toxicity is suspected
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance. Do not delay airway support and cardiac monitoring while obtaining consultation.
Look-alike / sound-alike and error prevention
- FLUoxetine vs paroxetine vs fluvoxamine—all are SSRIs with different indications and interaction profiles; verify generic name on MAR
- Prozac vs Sarafem—same active moiety but different labeled indications; confirm purpose of therapy
- Strength mix-ups—10 mg, 20 mg, and 40 mg capsules; 40 mg is a high unit dose
- Duplicate SSRI therapy—home fluoxetine plus newly ordered sertraline or escitalopram is a common reconciliation error
- Symbyax vs fluoxetine monotherapy—combination product includes olanzapine; do not interchange
- MAOI / linezolid orders—antibiotic linezolid is an MAOI-class interaction; treat as contraindicated unless documented specialist plan
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Onset / peak | Peak plasma concentrations approximately 6 to 8 hours after oral dose; clinical mood response lags by weeks |
| Half-life | Fluoxetine 1–3 days (acute) to 4–6 days (chronic); norfluoxetine 4–16 days—active drug persists weeks after stop |
| Morning dosing | Most regimens start AM; may reduce sleep disruption compared with evening dosing |
| Discontinuation | Gradual dose reduction preferred; abrupt stop may cause dizziness, sensory disturbances, insomnia, irritability—monitor during taper |
| Commonly missed | Home Prozac not on admission list; new tramadol or sumatriptan without SSRI interaction review |
| Ask pharmacy when | MAOI or linezolid ordered, serotonergic drug added, hepatic dose questions, or switching from/to another antidepressant |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Children, adolescents, young adults | Boxed warning for suicidality—weekly or more frequent monitoring early in therapy and after dose changes; involve caregivers |
| Bipolar disorder risk | Screen before treatment; antidepressant monotherapy may precipitate mania—fluoxetine/olanzapine combination is labeled for bipolar depression, not monotherapy |
| Serotonergic co-therapy | Tramadol, triptans, other SSRIs/SNRIs, lithium—heightened serotonin syndrome risk at initiation and dose increases |
| MAOI / linezolid exposure | Contraindicated combinations—fatal reactions reported; enforce 5-week fluoxetine washout before psychiatric MAOI |
| Seizure disorder | Use cautiously; seizures reported with fluoxetine overdose and in predisposed patients |
| Older adults / diuretic use | Greater hyponatremia risk—monitor sodium and mental status; fall precautions with confusion or unsteadiness |
| Hepatic impairment | Prolonged half-life in cirrhosis—use lower or less frequent doses per labeling |
| Pregnancy / third trimester | Neonatal complications reported with late-pregnancy SSRI exposure—respiratory distress, feeding difficulty, irritability; coordinate perinatal care |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Mood, suicidality, anxiety, sleep, and activation symptoms at each contact during the first months and after dose changes
- Signs of serotonin syndrome when serotonergic drugs are added—mental status, temperature, heart rate, blood pressure, tremor, reflexes
- Sodium and volume status in older adults, diuretic users, or patients with confusion, headache, or falls
- Bleeding in patients on anticoagulants or antiplatelet therapy
- Mania/hypomania symptoms when treating depression—sleep reduction, grandiosity, impulsivity
Document
- Dose, time, indication, and patient response including behavioral changes reported by family
- MAOI/linezolid screening and washout verification when antidepressants are switched
- Education on serotonergic drug interactions and when to seek urgent help
- Hold events, prescriber/pharmacist notification, and follow-up monitoring plan
Patient teaching
- Take as directed in the morning unless prescriber specifies otherwise; full benefit may take several weeks—do not stop suddenly without a taper plan
- Do not start MAO inhibitor diets, linezolid, or St. John’s wort without prescriber approval; tell all clinicians you take fluoxetine before new medicines
- Report worsening depression, suicidal thoughts, agitation, insomnia, or unusual behavior immediately—especially in teens and young adults
- Seek urgent care for high fever with agitation, muscle rigidity, fast heartbeat, or confusion—possible serotonin syndrome
- Contact local poison control or toxicology services per your facility’s overdose guidance if overdose is suspected—do not wait for symptoms to peak
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Suspected serotonin syndrome—mental status change plus autonomic or neuromuscular hyperactivity
- New MAOI, linezolid, or IV methylene blue order without documented washout or specialist plan
- Concomitant pimozide or thioridazine on MAR
- New suicidal ideation, self-harm behavior, or abrupt behavioral worsening in a young adult
- Symptomatic hyponatremia or seizure
- Severe rash, angioedema, or anaphylaxis after a dose
- Suspected overdose or patient cannot be safely aroused
- Order to switch to MAOI without confirmed 5-week fluoxetine-free interval
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Fluoxetine is familiar on behavioral health and medical units, but its long half-life makes interaction timing—not just today’s dose—the safety story. Build MAOI/linezolid and serotonergic drug checks into admission reconciliation and every new medication order.
1. Check-before-you-give protocol
- Right patient, drug, strength, route, time—and right serotonergic interaction screen
- Scan MAR and home list for MAOIs, linezolid, tramadol, triptans, duplicate SSRIs, and lithium
- Compare mood, behavior, and neurologic status to baseline; hold if activation or toxicity emerges
- Confirm washout documentation before any antidepressant class switch involving MAOIs
2. High-alert and safety badge
Not ISMP high-alert — boxed warnings for suicidality and serotonin syndrome still require enhanced monitoringMany institutions treat SSRI–MAOI proximity and linezolid co-orders as hard stops. Apply independent double-check habits for 40 mg capsules and for serotonergic stacks even when fluoxetine is not on a formal high-alert list.
3. Clinical workflow: hold and question rules
- If a postoperative patient receives new tramadol or a triptan while on fluoxetine, reassess serotonin syndrome risk the same shift and reinforce symptom teaching
- If infectious disease starts linezolid, hold fluoxetine and page pharmacy before administration unless a documented exception exists
- For suspected overdose, prioritize airway and cardiac monitoring; contact local poison control or toxicology per protocol—there is no specific antidote
4. Critical teach-back questions
- “Which new medicines must you avoid or ask about while taking fluoxetine?” (Patient should mention MAOIs, linezolid, other antidepressants without prescriber direction, and many pain/migraine drugs.)
- “What will you do if you have sudden agitation, fever, and muscle stiffness?” (Patient should seek urgent help and not take the next dose.)
5. Care coordination
Pharmacist: Review MAOI washout timing, linezolid plans, serotonergic combinations, hepatic dosing, and antidepressant switches
Prescriber / mental health: Notify for suicidality, mania, inadequate response after adequate trial, or need for taper when stopping
🧠 Quick mental checklist
- Has it been at least 14 days since any MAOI—and will the next prescriber need a 5-week fluoxetine-free interval before starting an MAOI?
- Is linezolid, tramadol, a triptan, or a second SSRI on today’s orders?
- Does this patient show agitation, hyperreflexia, fever, or autonomic swings suggesting serotonin syndrome?
- Am I monitoring suicidality and activation in a child, adolescent, or young adult during the first months or after a dose change?
- If I hold fluoxetine for toxicity, have I also held other serotonergic agents and activated the escalation pathway?
Fluoxetine NCLEX practice questions
This NCLEX-style clinical judgment practice set for fluoxetine uses a tabbed inpatient case (MAR, labs, history, nursing notes), then rotates priority action, cue recognition, trend interpretation with serotonergic interaction risk, documentation cloze, suicidality judgment, and matrix urgency sorting with Expected / Concerning / Urgent escalation columns—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Fluoxetine 20 mg PO daily AM — given 0800 daily × 10 days
- Tramadol 50 mg PO q6h PRN moderate pain — 1 dose at 1400 (new order today)
- Acetaminophen 650 mg PO q6h PRN fever — not given
- 2100: scheduled fluoxetine due; nurse reviewing case tabs before administration
- Admission: sodium 138 mmol/L, creatinine 0.9 mg/dL, glucose 96 mg/dL
- Today 1800: sodium 136 mmol/L; repeat sodium ordered
- No MAOI levels applicable; medication interaction review flagged SSRI + tramadol
- 22-year-old college student admitted for appendectomy, postoperative day 1
- Major depressive disorder; home fluoxetine 20 mg daily continued inpatient
- No MAOI history; no linezolid exposure
- Denies illicit drugs; family at bedside
- 1500: Pain 6/10; tramadol given with good effect per patient
- 1930: Patient restless, diaphoretic; temperature 38.4 °C; reports “shaky” legs
- 2000: Nurse notes bilateral knee reflexes brisk; patient anxious and unable to sit still
Answer key & rationale
Frequently asked questions
How long must nurses wait after stopping fluoxetine before an MAOI can start?
Prescribing information requires at least 5 weeks after stopping fluoxetine before starting an MAOI intended to treat psychiatric disorders, because of the long elimination half-life of fluoxetine and norfluoxetine and the risk of serotonin syndrome. At least 14 days must elapse between stopping an MAOI and starting fluoxetine.
What are the signs of serotonin syndrome nurses should act on with fluoxetine?
Labeling lists mental status changes (agitation, hallucinations, delirium, coma), autonomic instability (tachycardia, labile blood pressure, hyperthermia, diaphoresis), neuromuscular findings (tremor, rigidity, myoclonus, hyperreflexia), seizures, and GI symptoms (nausea, vomiting, diarrhea). Discontinue fluoxetine and other serotonergic agents and initiate supportive treatment immediately.
When should a nurse hold fluoxetine and contact the prescriber or pharmacist?
Hold for suspected serotonin syndrome, new MAOI or linezolid therapy without a documented washout plan, pimozide or thioridazine co-orders, new suicidal ideation or clinical worsening in a young adult, symptomatic hyponatremia, seizure, severe rash or allergic reaction, or suspected overdose.
Is there a specific antidote for fluoxetine overdose?
Prescribing information does not list a specific reversal agent. Overdose management is supportive, with activated charcoal considered for early presentations. Seizures, altered mental status, QT prolongation, and serotonin syndrome may occur—especially with other serotonergic co-ingestants. Contact local poison control or medical toxicology per facility protocol.
Why does fluoxetine carry a boxed warning for suicidality?
Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. Monitor all patients started on antidepressants for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the first few months and at dose changes. Families and caregivers should be alerted to report changes immediately.
Can fluoxetine be given with tramadol or sumatriptan?
Concomitant serotonergic drugs—including tramadol, triptans such as sumatriptan, other SSRIs, SNRIs, and lithium—increase serotonin syndrome risk. If combined use is clinically warranted, patients should be informed of the increased risk and monitored closely, particularly during initiation and dose increases.
References
-
U.S. National Library of Medicine. FLUOXETINE capsule — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9de65da4-73f8-4c88-8198-c92e63224ddb
-
Drugs and Lactation Database (LactMed). Fluoxetine. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501200/
-
U.S. Food and Drug Administration. FDA Drug Safety Communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-selective-serotonin-reuptake-inhibitor-ssri-antidepressant-use-during
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.